Cytotoxic response of ovarian cancer cell lines to IFN-γ is associated with sustained induction of IRF-1 and p21 mRNA by Burke, F et al.
Interferon-g (IFN-g) is a potent immunomodulatory and anti-
proliferative cytokine. The mechanisms(s) by which it inhibits
tumour cell growth and induces apoptosis has yet to be fully eluci-
dated. IFN-g has shown some success in the treatment of ovarian
cancer patients with minimal residual disease (Pujade-Lauraine et
al, 1996). We previously demonstrated that human IFN-g treat-
ment of human ovarian cancer xenografts in vivo induces tumour
cell growth arrest and apoptosis and increases mouse survival,
although not all xenografts respond (Burke et al, 1997).
One potential mechanism by which IFN-g inhibits cell growth is
via increased expression of the cyclin kinase inhibitor (CKI)
leading to a block in cell cycle progression and arrest of cell
growth (Chin et al, 1996). In addition to IFN-g, a number of other
cytokines also display growth inhibitory properties, some of which
have also been associated with CKI induction. For example,
p21 has been implicated in growth inhibition in response to
transforming growth factor b (TGF-b) in ovarian cancer cells
(Elbendary et al, 1994); to tumour necrosis factor a (TNF-a) in a
breast cancer cell line (Jeoung et al, 1995); to epidermal growth
factor (EGF) in a squamous cell carcinoma cell line (Fan et al,
1995; Jakus and Yeudall, 1996); and to IFN-a in haematopoietic
cell lines (Hobeika et al, 1997; Sangfelt et al, 1997). Another CKI,
p27, has also been associated with IFN-g-induced terminal growth
arrest in mammary carcinoma cell lines (Harvat et al, 1997).
The intracellular signalling pathways which follow binding to
IFN-g-specific cell surface receptors have been well-characterized
and involve the activation of  members of the Janus kinase family
(Jaks), Jak 1 and Jak 2 and stat1 (for signal transducer and acti-
vator of transcription (for review see Leaman et al, 1996). Data
suggest that transcriptionally active stat1 is required for the anti-
proliferative effects of IFN-g (Bromberg et al, 1996; Buard et al,
1998). A mutant cell line displaying only 20–30% of wild-type
transcriptional response did not undergo growth arrest in response
to IFN-g. Furthermore, activated stat1 proteins specifically recog-
nized the conserved stat-responsive element in the promoter of the
p21 gene and thus regulated the induction of p21 mRNA (Chin et
al, 1996). In addition to stat1 activation in response to IFN-g, the
transcription factor IRF-1 also plays a role in the regulation of cell
growth and apoptosis (reviewed by Taniguchi et al, 1997), and the
induction of p21 in response to g-irradiation is dependent on both
IRF-1 and wild-type p53 (Tanaka et al, 1996).
In order to optimize the use of growth inhibitory/apoptotic
cytokines such as IFN-g in ovarian cancer, we set out to assess the
following: the length of exposure to IFN-g required for apoptosis
of ovarian cancer cells; the signalling pathways that may correlate
with cell growth inhibition and apoptosis; and the differences
between IFN-g-sensitive and -resistant cells. We report here that
exposure to IFN-g for at least 2 days was necessary for an anti-
proliferative and apoptotic effect. Both sensitive and resistant cells
contained proteins able to bind a stat1-responsive element. p21
and IRF-1 were also induced in both sensitive and resistant cells
but this enhanced expression was only sustained in cells that were
subsequently killed by IFN-g.
METHODS
All reagents were provided by Sigma (Dorset, UK) unless other-
wise stated.
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Tissue culture
All cell lines were grown in a humidified atmosphere at 37°C (5%
carbon dioxide) under pyrogen-free conditions. Pasteur pipettes
were triple baked and all other pipettes were plastic. Tissue culture
medium and fetal calf serum (FSC; Life Technologies, Paisley,
UK) were chosen for their low endotoxin content. Cells were
grown in either RPMI-1640 or DMEM (SKOV-3) and 10% FCS.
With the exception of SKOV-3 all cell lines were also grown in the
presence of insulin (5 mg ml–1). A total of 2 mML -glutamine,
100 U ml–1 penicillin and 100 mg ml–1 of streptomycin were
included in the tissue culture medium.
Cell lines
PE01 was derived from ascites in a patient with poorly differenti-
ated adenocarcinoma. PE014 was obtained prior to chemotherapy
from a patient with well-differentiated serous adenocarcinoma
(both obtained and described in Langdon et al, 1988). OVCAR-3
originated from ascites in a patient with poorly differentiated
papillary adenocarcinoma (American Tissue Culture Collection
(ATTC), Rockville, MD, USA). SKOV-3 originated from ascites
in a patient with an ovarian adenocarcinoma and was also obtained
from ATCC. Cell lines were treated with a range of doses (200,
1000, or 5000 U ml–1) of recombinant human IFN-g (rhIFN-g).
Viable cells were clearly identifiable and counted using a haemo-
cytometer. PE01, PE014 and OVCAR-3 were all sensitive to the
growth effects of IFN-g, whilst SKOV-3 cells were resistant.
Interferon
rhIFN-g (RU 42369) was provided by Roussel UCLAF, as a
lyophilized preparation (20 MU per vial) and was more than 95%
pure. It was diluted in water and stored in aliquots at – 70°C prior
to use. Endotoxin levels were less than 0.24 UE per vial and the
specific activity was 2 ´ 107 units per mg protein.
Cell cycle analysis
Cells were seeded in 10-cm2 dishes at concentrations that would
ensure that the cells were semi-confluent at the time of harvest. At
appropriate time points, cells were pulsed for 45 min with 10 mM
bromodeoxyuridine (BrdU). The medium was subsequently
removed, cells were washed, scraped into phosphate-buffered
saline (PBS) and pelleted. The pellet was resuspended in 75%
ethanol and stored at 4°C prior to analysis. Labelling for BrdU and
DNA content were carried out following manufacturer’s instruc-
tions provided with the fluorescein isothiocyanate (FITC)-conju-
gated anti-BrdU antibody (Becton Dickinson, UK). The cells were
counter-stained with propidium iodide, and G1, S and G2 and were
gated out as appropriate by an experienced FACS operator.
Tunel assay
Cells were seeded in 10-cm2 dishes as outlined above, and approx-
imately 5 ´ 105 cells used to make cytospins. The cells were fixed
in 4% paraformaldehyde and stored at room temperature prior to
use. The method used was as described previously (Gavrieli et al,
1992).
Electron microscopy
PE01 cells were incubated for 7 days at either 0, 200 or
5000 U ml–1 of IFN-g. The cells were trypsinized and resuspended
in 2.5% glutaraldehyde in Sorensen’s phosphate buffer and
processed for electron microscopy using standard procedures.
One  mm toluidine blue stained sections were used to select repre-
sentative areas for ultrastructural investigation and for cell
counting.
Northern analysis
Total cellular RNA was isolated using TRI REAGENTTM
following manufacturer’s instructions. Fifteen micrograms total
cellular RNA was electrophoresed through a 1.4% agarose–
formaldehyde denaturing gel and capillary blotted onto ‘Biodyne
A’ membranes (Pall Ultrafine Filtration Corp, Glen Cove, NY,
USA). cDNA was labelled with 32P-dCTP using a random priming
kit (Stratagene, Cambridge, UK). Membranes were hybridized to
the  32P-labelled inserts of human cDNA probes under standard
conditions as outlined previously (Church and Gilbert, 1984).
Membranes were subsequently washed to high-stringency and
exposed to Kodak BioMax MS-1 film at –70°C with one intensi-
fying screen.
p21 mRNA synthesis
To assess the requirement for continued p21 mRNA synthesis,
PE01 cells were treated with IFN-g (5000 U ml–1) for 24 h.
Actinomycin D (10 mg ml–1) was added to cells and RNA
harvested 1, 3, 5 and 7 h later. Northern analysis was performed as
outlined above.
Table 1 Percentage of apoptotic cells as assessed by both ‘Tunel’ assay and morphometry. A minimum of ten high-power fields (100 ´ objective,
10 ´ eyepiece) were counted per cell line per time point and a mean taken
Cell line IFN-g U ml–1 No. of cells No. of apoptotic Apoptotic
counted cells cells (%)
PE01 0 465 23 4.9
200 318 33 10.3
5000 426 74 17.3
SKOV-3 0 428 8 1.9
200 343 11 3.2
5000 469 15 3.2
Assessment of apoptosis using the ‘Tunel’ assay together with morphology. Numbers represent the mean number of apoptotic cells per ten high-power fields
(´ 1000) following 4 days treatment with IFN-g.1238 F Burke et al
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cDNA probes
b-actin originated from Dr L Kedes (Stanford, CA, USA). The 0.7-
kb EcoR1–HindIII fragment in Bluescript was used. The 486-bp
NcoI cDNA fragment of p21 in pET21d-2 used for Northern
analysis was kindly provided by Dr T Hunt (ICRF, Clare Hall
Laboratories, South Mimms, UK). cDNAs for p15, 16, 18, 19, 27
were kindly provided by Dr G Peters (ICRF, PO Box 123, London,
UK). All were in Bluescript (KS+ and fragments isolated with
BamHI–EcoRI (for p16, 18, 19, 27) or EcoRI–HindIII (p15). IRF-
1 cDNA was provided by Dr Richard Pine (Public Health
Research, New York, NY, USA). This was extracted as an EcoR1
insert from pBluescript SK.
Cell extract preparations and EMSA
DNA-binding protein extracts were prepared as described previously
(Andrews and Faller, 1991) with minor modifications. Briefly, 2 ´
106 cells were washed in ice-cold PBS, pelleted and resuspended in
lysis buffer (10 mM HEPES, pH 7.9, 10 mM potassium chloride,
1m Mdithiothreitol, 1 mMEDTA, 1 mMEGTA, 0.2% NP-40, 0.5 mM
phenylmethylsulphonyl fluoride, 1 mM sodium vanadate, 1 mM b-
glycerol phosphate, 20 mM sodium fluoride, 1 mg ml–1 of aprotinin,
leupeptin and pepstatin. Following their resuspension, the extracts
were resuspended in buffer containing 25% glycerol and stored
at –70°C prior to use. For EMSA, double stranded oligonucleotide
for M67-SIE (GTGCATTTCCCGTAAATCTTGTCTACA) or a
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Figure 1 Cell growth assays. Growth assays of PE01 (A), OVCAR-3 (B), PE014 (C) and SKOV-3 (D) cells grown in 10% FCS. Cells were seeded at 5 ´ 104
per well in 6-well plates. Each time point was carried out in triplicate. n, Control; l, IFN-g 200 U ml–1; s, IFN-g 1000 U ml–1; u, 5000 U ml–1 IFN-gIFN-g and ovarian cancer cell lines 1239
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mutant SIE (GTGCATCCACCGTAAATCTTGTCTACA) was
endlabelled with [g -32P] adenosine 5¢ -triphosphate according to stan-
dard procedures. Binding reactions were performed in a total volume
of 20m l in 40mM HEPES, pH 7.9, 2mM magnesium
chloride, 8% Ficoll, 2mMdithiothreitol, 100mMsodium chloride,
poly(deoxyinosine–deoycytidine) (Pharmacia, 50m g ml–1). Extracts
were incubated with labelled oligonucleotides at room temperature
for 20min. Duplicate samples were also set up containing 50 times
excess of cold oligonucleotide as a competitor. Complexes were
separated on 4% acrylamide gels in 0.25 times Tris–borate EDTA at
4° C, dried down and detected by autoradiography.
Protein estimations and PAGE analysis
Protein estimations were carried out using the Bio-Rad protein
assay (Life Science Research Products, Herts, UK), and samples
were boiled for 2min and stored on ice prior to loading. A 10%
denaturing gel was made up for detection of stat1 protein. The
lysates were run at 120V for 1.5h on a AE-6400 Dual Mini slab
kit (Atto) using 1 ´running buffer (25mMTris; 192mMglycine;
0.1% sodium dodecyl sulphate). Rainbow markers (Amersham)
were used to determine product size.
Western blotting
Protein was transferred to nitrocellulose (Hybond-ECL, Amersham,
UK) which had been pre-equilibrated in transfer buffer (25mMTris,
192mm glycine, 20% methanol, pH 8.3) according to the method of
Towbin et al, 1979) using a Trans-Blot electrophoretic transfer cell
(Biorad) for 2–3h at 300mA. Blots were incubated in blocking
reagent (10% non-fat milk powder) overnight. Proteins were
detected using Amersham ECLTM. For Stat1, the cytosolic and
nuclei components obtained for the EMSA assay were used (10m g
per track) and monoclonal antibody used at 1m g ml–1 (Santa Cruz,
Autogen Bioclear, Wiltshire, UK).
Statistics
The unpaired Student’s t-test was used for statistical analysis.
RESULTS
Direct cell counting as a measure of cell growth
Four human ovarian cancer cell lines were grown under optimal
conditions in 10% FCS and assessed for their responsiveness to a
range of concentrations of IFN-g. In three of these lines. (PE01,
PE014 and OVCAR-3), IFN-ginhibited cell growth as shown in
5 m m
A B C
Figure 2Electron micrographs of PE01 cells cultured for 7 days. Cells were trypsinized prior to fixation. (A) Untreated, normal healthy tumour cells. (B) IFN-g
at 200U ml–1, culture contains normal and abnormal tumour cells, an apoptotic cell and cell debris. (C) IFN-g at 5000U ml–1. Early and late apoptotic cells are
evident, together with an apoptotic fragment and a necrotic cell
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Figure 3Time of IFN-g exposure to PE01 cells. PE01 cells were incubated
with IFN-g)(5000U ml–1 for times between 6h and 6 days, after which the
cells were trypsinized, reseeded at 5 ´104 cells per well in 6-well plates and
left for a further period of 6 days prior to counting. n, Untreated cells; nn, IFN-
g treated cells (5000U ml–1)1240 F Burke et al
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Figure 1. After 4–5 days of IFN-g treatment at 200 U ml–1, cell
counts in three cell lines were 29–40% of untreated cultures and
this was further reduced to 10–14% of untreated values by 7 days.
The effects of IFN-g were not dependent on optimal growth condi-
tions. IFN-g was also growth inhibitory for two cell lines (PE01
and OVCAR-3) that were cultured in the absence of serum (data
not shown).
The IFN-g sensitive PE01 cells were selected for further analysis.
The minimum concentration of IFN-g required to achieve growth
inhibition in this cell line was 100 U ml–1 (data not shown), and at
200, 1000 and 5000 U ml–1 significant growth inhibition was seen
after 4 and 7 days exposure (P < 0.0001 at 7 days for untreated vs
all three doses). In contrast, SKOV-3 cells were resistant to the
growth inhibitory actions of IFN-g at 200, 1000 and 5000 U ml–1.
As a further measure of growth inhibition in sensitive cells, we
used the thymidine analogue BrdU to assess the number of PE01
cells in S phase of the cell cycle. The time course of growth inhibi-
tion followed the same pattern as that described above. By 4 days,
only 10% of IFN-g-treated cells were synthesizing DNA compared
to 24% untreated cells.
IFN-g and apoptosis
The ‘Tunel’ assay was used together with an assessment of
morphology to measure cell death in treated cultures. These results
are shown in Table 1 and represent the mean number of apoptotic
cells per ten high power fields (´ 1000) following 4 days of treat-
ment with IFN-g. There was an increase in apoptosis after IFN-g
treatment of PE01 cells compared to untreated cells. The
percentage of cells that were apoptotic increased from 4.9% in
untreated to 17.3% following 4 days treatment of 5000 U ml–1 of
IFN-g. In contrast, the number of apoptotic cells did not signifi-
cantly change throughout treatment in SKOV-3.
Apoptosis was further investigated using electron microscopy
following treatment of PE01 with IFN-g for 7 days. Cells were
counted and assigned to a category on the basis of their general
appearance, with particular attention to the nucleus. The control
culture contained normal, healthy tumours cells (Figure 2A). The
culture that had been treated with IFN-g at 200 U ml–1 had a
high proportion of healthy normal cells, some abnormal and
a considerably increased number of apoptotic cells (Figure 2B).
Approximately half those cells treated with IFN-g at 5000 U ml–1
were dead, most of them being apoptotic (Figure 2C). The total
number of apoptotic cells increased from 0.3% in untreated cells to
4.2% with IFN-g (200 U ml–1), and 30.7% with 5000 U ml–1 of
IFN-g for 7 days.
Length of exposure to IFN-g
In order to assess how long IFN-g had to interact with the cells to
obtain maximal growth inhibitory effects, PE01 cells were incu-
bated with IFN-g for periods of 6 h to 6 days. Simply washing the
cells after these time points was not sufficient to remove IFN-g
bound to its receptor. Therefore, at appropriate times, IFN-g-
treated cells were trypsinized, washed and re-seeded (5 ´ 104
viable cells per well in 6-well plates) in culture medium without
IFN-g. After a further 6 days culture, cells were counted. These
results are shown in Figure 3. If cells were exposed to IFN-g for
between 6 and 48 h prior to trypsinization, they subsequently grew
to reach similar numbers as previously untreated cells. If cells
were treated with IFN-g for longer than 48 h prior to trypsiniza-
tion, they were not able to proliferate to the same extent when
replated in normal culture medium. Cell recovery was reduced by
72%, 86% and 90% as compared to untreated cells for 3 (P =
0.0003), 4 (P = 0.0007) and 6 (P = 0.0001) days prior to IFN-g
exposure respectively.
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Figure 4 Stat1 binding activity and protein in IFN-g-sensitive and resistant cells. (A) EMSA: Stat complexes were detected using M67-SIE, together with
excess cold competitor and mutant SIE. IFN-g-treated A431 cells were used as a positive control for stat1 activation. (B) Stat-1 protein expression in SKOV-3
and PE01 cells following treatment with IFN-g (200 U ml–1). Ten micrograms of cellular cytosolic component (B) or nuclei component (C) was loaded per track.
Western blotting analysis carried out as described in MethodsIFN-g and ovarian cancer cell lines 1241
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To further assess the molecular events that occur following IFN-
g treatment of ovarian cell lines, we studied PE01 and SKOV-3
cells that were sensitive and resistant to the growth inhibitory and
apoptotic effects of IFN-g respectively.
Stat-1 and the anti-proliferative effect of IFN-g
The ability of a cell to induce stat1 may be a requirement for an
anti-proliferative response to IFN-g. As shown in Figure 4A, PE01
cells had cis-inducible element-binding ability. This was subse-
quently confirmed by Western blotting. Figure 4B and 4C shows
the detection of stat1 in the cytosolic and nuclear compartments of
the cells. Figure 4A shows that SKOV-3 cells also had stat1-
binding activity. Indeed, there was clearly more protein for stat1 in
both cytoplasmic and nuclear compartments in the SKOV-3 cells
compared to PE01.
mRNA expression of CKIs following IFN-g treatment in
ovarian cancer cell lines
Northern analysis was used to assess changes in CKI mRNA
expression during IFN-g treatment of PE01 and SKOV-3 cells over
a period of 96 h. Members of both the INK family (p16, 15, 18,
19) and the p21 (p21, p27) family of CKIs were analysed at the
mRNA level. However, only p21 mRNA expression differed
significantly throughout treatment in both cell lines. In PE01 cells,
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Figure 5 p21 mRNA expression of IFN-g-treated sensitive and resistant cells. (A) PE01 cells. The expression of mRNA for CKI p21 following IFN-g
(5000 U ml–1) treatment. The blot was reprobed with b-actin as a loading control. Fifteen micrograms of total RNA were loaded per lane. (C) Integrated density
of p21 mRNA in PE01 cells after correcting for b-actin. (B) SKOV-3 cells. The expression of mRNA for CKI p21, following IFN-g (5000 U ml–1) treatment. The
blot was reprobed with b-actin as a loading control. Fifteen micrograms of total RNA were loaded per lane. (D) Integrated density of p21 mRNA in SKOV-3 cells
after correcting for b-actin
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Figure 6 p21 mRNA stability of IFN-g-treated PE01 cells. PE01 cells were
treated with IFN-g (5000 U ml–1) for 24 h. Cells were subsequently treated
with actinomycin D (10 mg ml–1) for 1, 3, 5, 7 h. Control cells were treated with
IFN-g only. The maintenance of p21 mRNA required continuing RNA
synthesis1242 F Burke et al
British Journal of Cancer (1999) 80(8), 1236–1244 © 1999 Cancer Research Campaign 
p21 mRNA was undetectable or expressed at low levels in IFN-g-
treated cells until 16 h. p21 mRNA increased at 24 h and this
increase was sustained at 48 and 96 h of IFN-g treatment.
Densitometry showed an approximately 15-fold increase in
mRNA expression at 24 h, which further increased to 40-fold at 48
and 96 h (Figure 5C, arbitrary units relative to b-actin). We also
assessed the p21 mRNA level in another sensitive cell line
OVCAR-3. The same pattern of mRNA expression was observed
with maximal effects at 48 h (data not shown).
In the SKOV-3 cells, which were not growth inhibited by IFN-g,
p21 mRNA was also induced but with different kinetics to those
observed with PE01 cells (Figure 5B). There was a rapid 60-fold
induction of p21 mRNA after just 1 h of treatment with IFN-g,
which gradually decreased thereafter (Figure 5D), arbitrary units
relative to b-actin). At a time when the p21 mRNA levels were
maximal in the IFN-g-sensitive PE01 cells that were irreversibly
growth arrested, the mRNA expression of p21 in SKOV-3 cells
was not significantly different from untreated cells.
p21 mRNA synthesis
We used actinomycin D treatment to see whether the gradual accu-
mulation in p21 mRNA was associated with continuous mRNA
synthesis. PE01 cells were treated with IFN-g for 24 h. At this
time, actinomycin D was added to cells and RNA was harvested
during a 7-h time period. Cells treated with IFN-g alone were used
as controls. p21 mRNA was detectable in IFN-g- and actinomycin
D-treated cells up to 3 h, after which it was no longer detectable.
As expected, p21 was detectable in all time points analysed where
cells had been treated with IFN-g alone (Figure 6). This experi-
ment clearly demonstrates that p21 mRNA synthesis must be
continuous.
IRF-1 mRNA expression of cells in response to IFN-g
IRF-1 has been associated with IFN-g-induced cell growth inhibi-
tion and apoptosis (Taniguchi et al, 1997) and the induction of p21
in response to g-irradiation is dependent on both IRF-1 and p53
(Tanaka et al, 1996). We assessed IRF-1 mRNA expression in
IFN-g-treated PE01 and SKOV-3 cells. In the PE01 cells there was
a gradual increase in mRNA which peaked at 48 h (Figure 7A, B),
arbitrary units relative to b-actin) and the induction was greater
than in untreated cells. The kinetics of expression of IRF-1 mRNA
in another IFN-g-sensitive cell line, OVCAR-3, resembled those of
PE01 cells (data not shown).
The treatment of SKOV-3 cells with IFN-g resulted in a rapid
increase of IRF-1 mRNA at 1 and 6 h. However, this induction
was not sustained and the pattern of expression at later time points
was similar to untreated cells (Figure 7C, D, arbitrary units relative
to b-actin).
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DISCUSSION
IFN-g displays growth inhibitory activities in a number of normal
and malignant cell lines and this cytokine may be of therapeutic
benefit to some patients with ovarian cancer (Pujade-Lauraine et
al, 1996). In this study we have shown that IFN-g is capable of
inducing both growth inhibition and apoptosis in the ovarian
cancer cell lines PE01, PE014 and OVCAR-3. In contrast, SKOV-
3 cells continue to proliferate in response to IFN-g.
The growth inhibitory effects of IFN-g in PE01 cells are not
immediate. It takes 3 days of continual IFN-g exposure for any
reduction in cell number and for an irreversible effect on cell
survival. Exposing the PE01 cells to IFN-g for a shorter period of
time had no effect on their subsequent ability to grow over a period
of 6 days. The importance of exposure time was highlighted in an
earlier study where we reported that the treatment of human
ovarian cancer xenografts with IFN-g for at least 14 days in vivo
was more effective than giving higher doses for shorter periods of
time (Burke et al, 1997).
Since transcriptionally active stat1 is required for the anti-
proliferative effect of IFN-g (Bromberg et al, 1996), we examined
the ability of resistant cells to recruit stat1 to the nucleus and
assessed their DNA binding activity. Nuclear components from
SKOV-3 cells demonstrated a stronger SIE-binding ability than
those from PE01 cells, and Western blotting confirmed that there
was a higher level of immunoreactive stat1. A recent paper has
been published describing the jak/stat signalling pathway in
mesothelioma cell lines with differing responses to IFN-g (Buard
et al, 1998). IFN-g phosphorylated jak2 and stat1, and induced the
transcription factor IRF-1 in three cell lines that were strongly
growth inhibited. Activation of the jak/stat pathway was weak or
absent in two further cell lines that were insensitive to IFN-g-
mediated growth inhibition. However, in two further cell lines,
IFN-g jak/stat signalling appeared normal, but the cells were only
weakly responsive to IFN-g. Thus, it would seem that cancer cell
lines accumulate signalling defects at various points in, and down-
stream from, the jak/stat pathway. The data described here would
support this conclusion.
One candidate gene downstream from the jak/stat pathway is
the CKI p21 (Chin et al, 1996). We looked for the regulation of
this CKI following IFN-g treatment of PE01 and SKOV-3 cells by
Northern analysis. Levels of p21 mRNA changed significantly
during IFN-g treatment of PE01 cells. There was a sustained
induction of the mRNA between 24 and 96 h, which correlates
well with the cell growth assay data where we found that sustained
treatment was important. Western blotting for p21 showed that the
protein was also undetectable until 24 h (unpublished data).
mRNA for p21 was also detectable by Northern analysis in the
cell line SKOV-3. There was a rapid increase in p21 mRNA
expression after only 1 h, which was not maintained. At a time
when PE01 cells were expressing high levels of p21 and under-
going irreversible cell growth arrest, the p21 mRNA expression in
SKOV-3 cells had returned to baseline levels. We were unable to
detect any changes in either PE01 or SKOV-3 cells in response to
IFN-g in five other CKIs investigated, although p27 has been asso-
ciated with mediating IFN-g-induced terminal growth arrest in
mammary carcinoma cell lines (Harvat et al, 1997).
The kinetics of p21 mRNA expression following IFN-g expo-
sure to PE01 cells were different from that following TGF-b1
treatment of the same cells, but again there was a correlation
between p21 kinetics and growth inhibition (data not shown).
PE01 cells were growth inhibited by TGF-b1, and p21 mRNA was
induced after only 1 h IFN-g treatment, but the increase was then
sustained. The kinetics of induction confirm previously published
data on other ovarian cell lines (Elbendary et al, 1994). TGF-b
treatment of SKOV-3 cells did not significantly affect their growth
compared to untreated cells (P = 0.09) and there were no changes
in p21 mRNA throughout the treatment period.
Using actinomycin D we showed that the maintenance of the
increased p21 mRNA required continous mRNA synthesis. Since
we were unable to detect p21 mRNA in cells pretreated with IFN-
g after 3 h of actinomycin D treatment, we performed transient
transfection assays to directly assess p21 gene transcription in
response to IFN-g. The WWP-luc plasmid was provided by Dr
Bert Vogelstein (John Hopkins University, USA) and carries the
p21 promoter sequence fused to a promoterless luciferase gene.
There was little difference in p21 promoter gene transcription in
treated and untreated cells. It is likely, therefore, that the response
to IFN-g requires regulatory regions of the gene that are not in this
reporter construct. Two of the three known SIE sites 5¢ of the gene
are outside the fragment in the construct. As a positive control for
this experiment, we co-transfected PE01 cells with a p21 promoter
construct together with wild-type p53 and demonstrated that the
p53-dependent response was operational in PE01 cells when trans-
fected with this construct (data not shown).
Finally, we assessed IRF-1 mRNA changes in PE01 and SKOV-
3 cells in response to IFN-g. IRF-1 mRNA gradually increased in
IFN-g treated PE01 cells relative to untreated cells, at a time when
these cells become irreversibly growth arrested. This gradual
increase in expression presented a very similar pattern to that
observed with p21 mRNA. IRF-1 mRNA expression in SKOV-3
cells in response to IFN-g also resembled that for p21. There was
an initial induction which then slowly declined. Thus SKOV-3
cells were able to induce either p21 or IRF-1 in response to IFN-g.
However, there seemed be a defect in their ability to sustain the
induction of these genes.
Our data suggest that there may be a critical time window
between 48 and 72 h when PE01 cells become committed to a
pathway leading to irreversible growth arrest and subsequent
apoptosis when exposed to IFN-g. A number of papers have been
published recently suggesting target genes responsible for the anti-
proliferative effects of IFN-g. The data from these papers, together
with the data we present here, suggest that different cell lines have
signalling defects at different levels. For example, some cells may
have defects in their ability to induce jaks or stats, whilst others
have defects in being able to activate IRF-1. Other cells may have
the ability to induce all of these, but are not able to sustain this
induction. The SOCS (suppressor of cytokine signalling) proteins
are a family of negative regulators of cytokine signal transduction
(for review see Nicholson and Hilton, 1998). They are induced by
stats and inhibit cytokine signal transduction via a negative feed-
back loop. One member of this family, JAB, is strongly induced by
IFN-g and its overexpression may be involved in IFN-g resistance
in some cells (Sakamoto et al, 1998). It is possible that our IFN-g-
insensitive cell line may overexpress one or more of these
proteins.
Preliminary data from this laboratory suggest that tumour cells
from freshly isolated ovarian cancer as cites behave in a similar
way to the cell lines studied here (L Wall, unpublished data).
Whilst tumour cells from most ascitic samples undergo apoptosis
in response to IFN-g, a minority are resistant. The molecular
analysis described here may help in determining markers of1244 F Burke et al
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response to IFN-g and in the identification of patients most likely
to benefit from IFN-g therapy.
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